Heparanase expression correlates with malignant potential in human colon cancer - PubMed (original) (raw)

. 2005 Apr;131(4):229-37.

doi: 10.1007/s00432-004-0644-x. Epub 2004 Dec 30.

Y Naomoto, T Ohkawa, M Takaoka, R Ono, T Murata, M Gunduz, Y Shirakawa, T Yamatsuji, M Haisa, J Matsuoka, H Tsujigiwa, H Nagatsuka, M Nakajima, N Tanaka

Affiliations

• PMID: 15625607
• DOI: 10.1007/s00432-004-0644-x

Heparanase expression correlates with malignant potential in human colon cancer

T Nobuhisa et al. J Cancer Res Clin Oncol. 2005 Apr.

Abstract

Purpose: Heparanase cleaves carbohydrate chains of heparan sulphate proteoglycans and is an important component of the extracellular matrix. This study was designed to determine the relation between heparanase expression and prognosis of patients with colon cancer.

Methods: The study included 54 patients (35 males and 19 females) who underwent colorectal resection for colorectal cancer between January 1992 and December 1994. Expression of heparanase protein and mRNA were determined and correlated with various clinicopathological parameters. In vitro studies were also performed to examine tumor invasion and to test the effects of heparanase inhibition, and in vivo studies were performed to examine tumor metastasis and prognosis.

Results: Heparanase expression was detected in the invasion front of the tumor in 37 of 54 (69%) colon cancer samples, whereas 17 of 54 (31%) tumors were negative. Expression of heparanase was significantly more frequent in tumors of higher TNM stage (P=0.0481), higher Dukes stage (P=0.0411), higher vascular infiltration (P=0.0146), and higher lymph vessel infiltration (P=0.0010). Heparanase expression in colon cancers correlated significantly with poor survival (P=0.0361). Heparanase-transfected colon cancer cells exhibited significant invasion compared with control-transfected colon cancer cells (P=0.001), and the peritoneal dissemination model also showed the malignant potential of heparanase-transfected cells, as assayed by number of nodules (P=0.017) and survival (P=0.0062). Inhibition of heparanase significantly reduced the invasive capacity of cancer cells (P=0.003).

Conclusions: Heparanase is a marker for poor prognosis of patients with colon cancer and could be a suitable target for antitumor therapy in colon cancer.

PubMed Disclaimer

Similar articles

• Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis.
  Beckhove P, Helmke BM, Ziouta Y, Bucur M, Dörner W, Mogler C, Dyckhoff G, Herold-Mende C. Beckhove P, et al. Clin Cancer Res. 2005 Apr 15;11(8):2899-906. doi: 10.1158/1078-0432.CCR-04-0664. Clin Cancer Res. 2005. PMID: 15837740
• [Effect of exogenous expression of heparanase gene on invasive ability of colorectal cancer cell line HT29].
  Liu Y, Ding YQ, Xin XY, Han LF, Liang L. Liu Y, et al. Ai Zheng. 2005 Dec;24(12):1427-30. Ai Zheng. 2005. PMID: 16351786 Chinese.
• Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma.
  Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Tang W, et al. Mod Pathol. 2002 Jun;15(6):593-8. doi: 10.1038/modpathol.3880571. Mod Pathol. 2002. PMID: 12065771
• The role of heparanase in gastrointestinal cancer (Review).
  Naomoto Y, Takaoka M, Okawa T, Nobuhisa T, Gunduz M, Tanaka N. Naomoto Y, et al. Oncol Rep. 2005 Jul;14(1):3-8. Oncol Rep. 2005. PMID: 15944760 Review.
• Mammalian heparanase as mediator of tumor metastasis and angiogenesis.
  Vlodavsky I, Elkin M, Pappo O, Aingorn H, Atzmon R, Ishai-Michaeli R, Aviv A, Pecker I, Friedmann Y. Vlodavsky I, et al. Isr Med Assoc J. 2000 Jul;2 Suppl:37-45. Isr Med Assoc J. 2000. PMID: 10909416 Review.

Cited by

• Heparanase Promotes Tumor Growth and Liver Metastasis of Colorectal Cancer Cells by Activating the p38/MMP1 Axis.
  Liu X, Zhou ZH, Li W, Zhang SK, Li J, Zhou MJ, Song JW. Liu X, et al. Front Oncol. 2019 Apr 2;9:216. doi: 10.3389/fonc.2019.00216. eCollection 2019. Front Oncol. 2019. PMID: 31001480 Free PMC article.
• Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.
  Hermano E, Lerner I, Elkin M. Hermano E, et al. Cell Mol Life Sci. 2012 Aug;69(15):2501-13. doi: 10.1007/s00018-012-0930-8. Epub 2012 Feb 14. Cell Mol Life Sci. 2012. PMID: 22331282 Free PMC article. Review.
• Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.
  Katakam SK, Pelucchi P, Cocola C, Reinbold R, Vlodavsky I, Greve B, Götte M. Katakam SK, et al. Front Oncol. 2020 May 14;10:774. doi: 10.3389/fonc.2020.00774. eCollection 2020. Front Oncol. 2020. PMID: 32477959 Free PMC article.
• MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase.
  Sheng N, Zhang L, Yang S. Sheng N, et al. Exp Ther Med. 2018 Feb;15(2):1927-1933. doi: 10.3892/etm.2017.5608. Epub 2017 Dec 11. Exp Ther Med. 2018. PMID: 29434786 Free PMC article.
• Versatile role of heparanase in inflammation.
  Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM, Elkin M. Goldberg R, et al. Matrix Biol. 2013 Jun 24;32(5):234-240. doi: 10.1016/j.matbio.2013.02.008. Epub 2013 Mar 13. Matrix Biol. 2013. PMID: 23499528 Free PMC article. Review.

References

1. 1. Biochem J. 1997 Jul 1;325 ( Pt 1):229-37 - PubMed
2. 1. Br J Cancer. 2002 Apr 22;86(8):1270-5 - PubMed
3. 1. Annu Rev Biochem. 1991;60:443-75 - PubMed
4. 1. Surg Gynecol Obstet. 1948 Oct;87(4):457-64 - PubMed
5. 1. J Cell Biochem. 1988 Feb;36(2):157-67 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer